<DOC>
	<DOC>NCT03057977</DOC>
	<brief_summary>The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.</brief_summary>
	<brief_title>EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Male or female patient age &gt;= 18 years at screening. For Japan only: Age &gt;= 20 years at screening Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association Classification) class IIIV and reduced EF (Ejection Fraction) (LVEF (Left Ventricular Ejection Fraction) &lt;=40%) and elevated NTproBNP (Nterminal of the prohormone brain natriuretic peptide) If EF &gt;= 36% to &lt;= 40%: NTproBNP &gt;= 2500 pg/ml If EF &gt;= 31% to &lt;= 35%: NTproBNP &gt;= 1000 pg/ml If EF&lt;= 30% NTproBNP &gt;= 600 pg/ml Appropriate dose of medical therapy for HF consistent with prevailing local and international CV (Cardiovascular) guidelines, stable for at least 1 week prior to Visit 1 Appropriate use of medical devices such as cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international CV guidelines, unless it is implanted within 3 months prior to Visit 1 Signed and dated written ICF (Informed Consent Form) Further inclusion criteria apply Exclusion criteria: Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1 Heart transplant recipient, or listed for heart transplant Acute decompensated HF Systolic blood pressure (SBP) &gt;= 180 mmHg at Visit 2. Symptomatic hypotension and/or a SBP &lt; 100 mmHg Indication of liver disease Impaired renal function, defined as eGFR (Estimated Glomerular Filtration Rate) &lt; 20 mL/min/1.73 m2 (CKDEPI (Chronic Kidney Disease Epidemiology Collaboration Equation)) or requiring dialysis History of ketoacidosis Treatment with any SGLT (Sodiumglucose cotransporter)2 inhibitor or combined SGLT1 and 2 inhibitor Currently enrolled in another investigational device or drug study Known allergy or hypersensitivity to empagliflozin or other SGLT2 inhibitors Women who are pregnant, nursing, or who plan to become pregnant while in the trial Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>